Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.25 Average Price Target from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has received an average recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $7.25.

Several equities analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $4.33 on Friday. Recursion Pharmaceuticals has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -2.43 and a beta of 0.93. The company’s fifty day moving average price is $5.18 and its 200-day moving average price is $5.12.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. The firm’s revenue was down 80.1% on a year-over-year basis. On average, equities research analysts anticipate that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in RXRX. TD Waterhouse Canada Inc. raised its position in Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after purchasing an additional 2,200 shares during the period. AlphaQuest LLC bought a new position in shares of Recursion Pharmaceuticals during the first quarter valued at about $36,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock worth $46,000 after buying an additional 4,446 shares during the period. Janney Montgomery Scott LLC bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $51,000. Finally, PFG Investments LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $53,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.